Sarepta Therapeutics (FRA:AB3A) EV-to-Revenue

: 8.70 (As of Today)

View and export this data going back to 1997. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sarepta Therapeutics's enterprise value is €10,029 Mil. Sarepta Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €1,153 Mil. Therefore, Sarepta Therapeutics's EV-to-Revenue for today is 8.70.

The historical rank and industry rank for Sarepta Therapeutics's EV-to-Revenue or its related term are showing as below:

FRA:AB3A' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.95 Med: 25.75 Max: 58108.72
Current: 8.6

During the past 13 years, the highest EV-to-Revenue of Sarepta Therapeutics was 58108.72. The lowest was 5.95. And the median was 25.75.

FRA:AB3A's EV-to-Revenue is ranked worse than
52.28% of 1031 companies
in the Biotechnology industry
Industry Median: 7.7 vs FRA:AB3A: 8.60

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-23), Sarepta Therapeutics's stock price is €109.30. Sarepta Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €12.41. Therefore, Sarepta Therapeutics's PS Ratio for today is 8.81.

Sarepta Therapeutics EV-to-Revenue Historical Data

The historical data trend for Sarepta Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

24.44

23.45

9.81

11.82

7.04

Sarepta Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															11.82	12.55	10.15	9.93	7.04

Competitive Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sarepta Therapeutics EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's EV-to-Revenue falls into.

Sarepta Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sarepta Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	10028.999	/	1152.653
	=	8.70

Sarepta Therapeutics's current Enterprise Value is €10,029 Mil.
Sarepta Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,153 Mil.

Sarepta Therapeutics (FRA:AB3A) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sarepta Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	109.30	/	12.406
	=	8.81

Sarepta Therapeutics's share price for today is €109.30.
Sarepta Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.41.

Sarepta Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (FRA:AB3A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (FRA:AB3A) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SRPT:USA AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (FRA:AB3A) Headlines

No Headlines